Literature DB >> 25008160

Evaluation of toxicological hazards from medical radioiodine administration.

Miriam Van Dyke1, Mohan Punja, Michael J Hall, Ziad Kazzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25008160      PMCID： PMC4371044          DOI： 10.1007/s13181-014-0412-5

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN： 1556-9039


× No keyword cloud information.
  6 in total

Review 1.  Radiation dose to patients and relatives incident to 131I therapy.

Authors:  P B Zanzonico
Journal:  Thyroid       Date:  1997-04       Impact factor: 6.568

2.  Large-body radiation doses following radioiodine therapy.

Authors:  W D Leslie; J Havelock; R Palser; D N Abrams
Journal:  Nucl Med Commun       Date:  2002-11       Impact factor: 1.690

3.  Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism.

Authors:  S F Barrington; M J O'Doherty; A G Kettle; W H Thomson; P J Mountford; D N Burrell; R J Farrell; S Batchelor; P Seed; L K Harding
Journal:  Eur J Nucl Med       Date:  1999-07

4.  Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.

Authors:  James C Sisson; John Freitas; Iain Ross McDougall; Lawrence T Dauer; James R Hurley; James D Brierley; Charlotte H Edinboro; David Rosenthal; Michael J Thomas; Jason A Wexler; Ernest Asamoah; Anca M Avram; Mira Milas; Carol Greenlee
Journal:  Thyroid       Date:  2011-03-18       Impact factor: 6.568

5.  Release of patients after therapy with unsealed radionuclides.

Authors: 
Journal:  Ann ICRP       Date:  2004

6.  Recommended restrictions after 131I therapy: measured doses in family members.

Authors:  I Mathieu; J Caussin; P Smeesters; A Wambersie; C Beckers
Journal:  Health Phys       Date:  1999-02       Impact factor: 1.316
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.